Biologic therapy for psoriasis: the tumor necrosis factor inhibitors infliximab and etanercept.
Biologic therapy for psoriasis: the tumor necrosis factor inhibitors infliximab and etanercept.
复制标题
牛皮癣的生物疗法：肿瘤坏死因子抑制剂英夫利昔单抗和依那西普。
DOI：
--
复制
发表时间：
2003
期刊：
影响因子：
--
通讯作者：
Ritu Saini
中科院分区：
文献类型：
--
作者：
J. Weinberg;Ritu Saini
在过去的几年中，银屑病研究的主要焦点之一是开发新的生物疗法。这些疗法的目的是提供选择性的、免疫定向的干预，希望这种特异性将导致比传统疗法更少的副作用。在这篇由两部分组成的综述中，我们介绍了最有可能首次用于临床的4种生物药物的最新进展：英夫利昔单抗、依那西普、依法单抗和阿法西普。将回顾每种药物的结构和作用机制，以及最新的临床经验和安全性数据。本文将重点介绍抑制肿瘤坏死因子α (tnf - α)的治疗方法。
During the past several years, one of the major focuses in psoriasis research has been the development of novel biologic therapies for this disease. The aim of these therapies is to provide selective, immunologically directed intervention, with the hope that such specificity will result in fewer side effects than traditional therapies. In this 2-part review, we present an update on the progress of the 4 biologic agents that most likely will be the first available for clinical use: infliximab, etanercept, efalizumab, and alefacept. The structure and mechanism of each drug will be reviewed, as well as the most recent clinical experience and safety data. The first article of this review will focus on the therapies that inhibit tumor necrosis factor alpha (TNF-alpha).